fda warning letters compounded semaglutide october 2025 Semaglutide: The Drug of Today and a Steppingstone to Tomorrow FDA Drug Recalls and Warnings:

Notably, when an acylated GCGR agonist was administered alone, it led to approximately 20% weight loss in mice on a high-fat diet, and this weight loss was further enhanced when the GCGR agonist was combined with a GLP-1R/GIPR co-agonist

Discuss options with a licensed clinician

Larger, more rigorously designed studies are needed before these findings alter clinical practice, she said

Now, if you're treating bipolar depression, it's a wonderful drug, very potent, very effective

Leading multinational corporations (MNCs) such as Eli Lilly, Pfizer, Roche, AstraZeneca, and Gilead have all entered the small-molecule GLP-1RA race

Reta could help mitigate that physiologic change, she says, but emphasizes that more research is needed to confirm this